Drug Trial Radar · NCT04445064
Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.
Last checked: Nov 20, 2026Latest source record: Dec 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
17
Actual
Start
Aug 14, 2020
Primary completion
Jun 8, 2024
Study completion Mar 20, 2025
Sponsor
- Lead sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de LouvainAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this project is to realize a randomized open-label study (EudraCT number: 2020-000120-19) to evaluate the safety and the anti-tumor activity of peptide(s)-based immunotherapy in an umbrella window pre-operative opportunity phase II study in patients with squamous cell carcinoma of the head and neck.
Conditions
- Oropharynx Squamous Cell Carcinoma
- Larynx Squamous Cell Carcinoma
- Hypopharynx Squamous Cell Carcinoma
- Oral Cavity Squamous Cell Carcinoma
Interventions
IO102Biological
100µg each week during the 3 weeks prior to curative treatment (total of 3 to 4 doses maximum)
IO103Biological
100µg each week during the 3 weeks prior to curative treatment (total of 3 to 4 doses maximum)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with a T-cell peptide-specific response to the vaccine as assessed by an interferon(INF)-γ ELISpot assay.Time frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.